Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0N0RU
|
||||
| Former ID |
DAP000276
|
||||
| Drug Name |
Bexarotene
|
||||
| Synonyms |
Bexaroteno; Bexarotenum; Targret; Targretin; Targretyn; Targrexin; Bexarotene [USAN]; Elan brand of bexarotene;Ligand brand of bexarotene; LG 1069; LG100069; LG1069; LG69 compound; LGD 1069; LGD1069; LG-100069; LGD-1069; Targretin (TN); Targretin-gel; Bexarotene (USAN/INN); P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; 4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid; 4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid; 4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid; 9RA
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Eisai Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H28O2
|
||||
| InChI |
InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26)
|
||||
| InChIKey |
NAVMQTYZDKMPEU-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 153559-49-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7978490, 10219206, 11528625, 14876119, 17397261, 43137306, 46509119, 50125754, 50156197, 53790324, 56310969, 56313259, 56313930, 56352964, 57288573, 57333349, 74382986, 85246146, 87550948, 92308910, 93167039, 103274364, 103941130, 104379861, 118314715, 124893632, 124893633, 125341807, 126591248, 126646347, 126667092, 127324027, 127324028, 127324029, 127324030, 127324031, 127324032, 127324033, 128675752, 131300153, 131407703, 134220606, 134337590, 135037531, 135650520, 135692419, 136340346, 136946490, 137002663, 142405765
|
||||
| ChEBI ID |
ChEBI:50859
|
||||
| SuperDrug ATC ID |
L01XX25
|
||||
| SuperDrug CAS ID |
cas=153559490
|
||||
| Target and Pathway | |||||
| Target(s) | Retinoic acid receptor RXR-alpha | Target Info | Modulator | [556264] | |
| KEGG Pathway | PPAR signaling pathway | ||||
| PI3K-Akt signaling pathway | |||||
| Thyroid hormone signaling pathway | |||||
| Adipocytokine signaling pathway | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Bile secretion | |||||
| Hepatitis C | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Thyroid cancer | |||||
| Small cell lung cancer | |||||
| Non-small cell lung cancer | |||||
| PANTHER Pathway | Vitamin D metabolism and pathway | ||||
| Reactome | RORA activates gene expression | ||||
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||||
| Recycling of bile acids and salts | |||||
| PPARA activates gene expression | |||||
| Import of palmitoyl-CoA into the mitochondrial matrix | |||||
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||||
| Regulation of pyruvate dehydrogenase (PDH) complex | |||||
| Endogenous sterols | |||||
| Transcriptional activation of mitochondrial biogenesis | |||||
| Activation of gene expression by SREBF (SREBP) | |||||
| Transcriptional regulation of white adipocyte differentiation | |||||
| Nuclear Receptor transcription pathway | |||||
| Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Circadian Clock | |||||
| WikiPathways | Vitamin A and Carotenoid Metabolism | ||||
| NRF2 pathway | |||||
| Nuclear Receptors Meta-Pathway | |||||
| Farnesoid X Receptor Pathway | |||||
| PPAR Alpha Pathway | |||||
| Vitamin D Receptor Pathway | |||||
| Pregnane X Receptor pathway | |||||
| Constitutive Androstane Receptor Pathway | |||||
| Liver X Receptor Pathway | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||||
| Activation of Gene Expression by SREBP (SREBF) | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Adipogenesis | |||||
| Circadian Clock | |||||
| Nuclear Receptors | |||||
| Vitamin D Metabolism | |||||
| References | |||||
| Ref 536739 | Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs. 2008 Jun;13(2):345-61. | ||||
| Ref 539848 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2807). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.